摘要
目的比较布地奈德与孟鲁司特治疗儿童轻度持续性哮喘的临床疗效。方法选择2016年6月~2017年6月在我院诊断治疗的儿童轻度持续性哮喘患儿80例为研究对象,随机分为布地奈德组与孟鲁司特组各40例。布地奈德组给予吸入用布地奈德混悬液治疗,孟鲁司特组给予孟鲁司特片口服。比较治疗前、治疗后血EOS水平及呼出气一氧化氮(Fe No)水平,日间症状评分与夜间症状评分。结果两组治疗后日间症状评分与夜间症状评分显著低于治疗前,差异有统计学意义(P<0.05)。两组治疗后血EOS水平显著低于治疗前,差异有统计学意义(P<0.05);治疗后布地奈德组血EOS水平显著低于孟鲁司特组,差异有统计学意义(P<0.05)。布地奈德组治疗后Fe No水平显著低于治疗前,差异有统计学意义(P<0.05);治疗后布地奈德组Fe No水平显著低于孟鲁司特组,差异有统计学意义(P<0.05)。结论布地奈德与孟鲁司特治疗儿童轻度持续性哮喘均能有效改善临床症状,但布地奈德能降低嗜酸性粒细胞水平以及Fe No水平。
Objective To compare the clinical efficacy between budesonide with montelukast in the treatment of mild persistent asthma in children. Methods A total of 80 children with mild persistent asthma from June 2016 to June 2017 were selected as subjects, and were randomly divided into the budesonide group and the montelukast group, each of 40 cases. The budesonide group was treated with budesonide, and the montelukast group was treated with montelukast. EOS and FeNo levels, daytime symptom score and night symptom score before and after treatment between two groups were compared. Results After treatment, daytime symptom score and night symptom score in the two groups were lower than those before treatment, which showed significant difference（P 〈0.05）. After treatment, EOS in the budesonide was lower than that before treatment（P 〈0.05）; After treatment, EOS in the budesonide was lower than that in the montelukast group（P 〈0.05）. After treatment, FeNo in the budesonide was lower than that before treatment（P 〈0.05）; After treatment, FeNo in the budesonide was lower than that in the montelukast group（P 〈0.05）. Conclusion Both budesonide and montelukast in the treatment of children with mild persistent asthma can effectively improve the clinical symptoms, but budesonide can reduce the level of EOS and FeNo.
出处
《中国医药科学》
2017年第24期74-76,162,共4页
China Medicine And Pharmacy
关键词
布地奈德
孟鲁司特
儿童哮喘
持续性
Budesonide
Montelukast
Asthma in children
Persistent
